An experimental oncolytic virus therapy developed by CG Oncology helped clear tumors in 75% of bladder cancer patients in a Phase 3 study.
The therapy, known as cretostimogene grenadenorepvec, or creto for short, is a virus designed to infect and destroy tumor cells. It’s a form of immunotherapy — as the virus spreads through tumor cells and kills them, the ruptured cells release tiny cancer markers that alert immune cells, which join the attack.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.